( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Jazz Pharmaceuticals plc

13:30 GMT Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the...


13 Feb, 2018, 21:05 GMT Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 fourth quarter and full year financial results on Tuesday,...


08 Feb, 2018, 21:15 GMT National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN®) added Vyxeos™ (daunorubicin and...


02 Jan, 2018, 21:05 GMT Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 36th Annual J.P....


21 Dec, 2017, 13:30 GMT Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...


07 Dec, 2017, 21:05 GMT Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets...


04 Dec, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer,...


09 Nov, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


07 Nov, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results

Total Revenues Increased 10% to $412 Million Launched Vyxeos in the U.S. in August 2017 Vyxeos EU Marketing Authorization Application Submission...


03 Nov, 2017, 12:30 GMT Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia

Vyxeos granted accelerated assessment review status from European Medicines Agency's Committee for Medicinal Products for Human Use Jazz...


01 Nov, 2017, 13:29 GMT Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting

Nineteen abstracts accepted for three Jazz hematology/oncology products Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that thirteen...


24 Oct, 2017, 21:05 BST Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017,...


12 Sep, 2017, 13:30 BST Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company was named to Fortune magazine's list of fastest growing companies for...


01 Sep, 2017, 17:45 BST Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that the initial purchasers of the recently announced private...


30 Aug, 2017, 21:05 BST Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Wells Fargo...


29 Aug, 2017, 11:30 BST Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products

Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75...


18 Aug, 2017, 12:00 BST Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced an offering by Jazz Investments I Limited, its wholly-owned...


17 Aug, 2017, 21:13 BST Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of...


08 Aug, 2017, 21:05 BST Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results

Received FDA Approval of Vyxeos for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with...


03 Aug, 2017, 15:15 BST Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m....


26 Jul, 2017, 21:05 BST Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH ("XLp") for the rights to...


24 Jul, 2017, 21:05 BST Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 second quarter financial results on Tuesday, August 8, 2017,...


06 Jun, 2017, 22:05 BST Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Data were presented in a poster presentation at the annual SLEEP Meeting; JZP-110 U.S. NDA submission planned for later this year Jazz...


06 Jun, 2017, 22:01 BST Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy

Data were presented in a poster presentation at the annual SLEEP Meeting; JZP-110 U.S. NDA submission planned for later this year Jazz...